Fibrin clot degradation

Cross-linked fibrin degradation products

(xFDPs)

Order
Quantity
Price
Status
200 µg 265 € available


Art. No. F011
Synonym xFDPs
Background info Human fibrinogen is incubated together with human FXIII, activated human thrombin and Ca2+ at 37°C until saturation of fibrin-crosslinks is achieved. Degradation products are generated through proteolysis by activated human plasmin and isolated using gel filtration chromatography.
Molecular Weight 50-200 kDa
Appearance Liquid
Formulation xFDPs are stored in a buffer containing 20 mM Tris-HCl pH 7.4, 500 mM NaCl
Storage Store at ≤ -20°C
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.
  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland